Skip to content

Arcutis Biotherapeutics, Inc. ARQT Convertible Preferred Stock Authorized Shares

Convertible Preferred Stock Authorized Shares at other companies

Ligand Pharmaceuticals logo
Ligand PharmaceuticalsLGND
5M0.0%
Rhythm Pharmaceuticals, Inc. logo
Rhythm Pharmaceuticals, Inc.RYTM
9.9M
Immunovant, Inc. logo
Immunovant, Inc.IMVT
10M
ALN
Alnylam PharmaceuticalsALNY
5M0.0%
Incyte logo
IncyteINCY
BridgeBio Pharma logo
BridgeBio PharmaBBIO

Other financials

Income statement

See full
Revenue$105.4M+60.1%
Gross profit$95.6M+67.7%
Operating income-$9.1M+62.9%
Net income-$11.3M+54.9%
EPS (diluted)-$0.09+55.0%

Balance sheet

See full
Cash & equivalents$35.1M-34.7%
Total debt$114.7M+3.5%
Total equity$189.6M+32.9%
Total assets$460.0M+33.7%

Cash flow

See full
Operating cash flow$2.2M+107%
CapEx--100%
Free cash flow$2.2M+107%

Valuation

See full
Market cap$3.29B+57.5%

Profitability

See full
Gross margin90.9%+2.5pp
Operating margin-12%-5.7pp
Net margin-13.9%-6.6pp
FCF margin-52.5%-21.9pp

Returns & leverage

See full
Return on equity-28.2%-13.0pp
Debt / equity0.6×-0.2×
Current ratio2.7×-0.9×

Where this comes from

Reported directly by Arcutis Biotherapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:PreferredStockSharesAuthorized.

The official record: Arcutis Biotherapeutics, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Arcutis Biotherapeutics, Inc.'s convertible preferred stock authorized shares.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Arcutis Biotherapeutics, Inc.'s convertible preferred stock authorized shares?
Arcutis Biotherapeutics, Inc. (ARQT) reported convertible preferred stock authorized shares of 10M in Q1 2026.
How has Arcutis Biotherapeutics, Inc.'s convertible preferred stock authorized shares changed year-over-year?
Arcutis Biotherapeutics, Inc.'s convertible preferred stock authorized shares decreased by 0.0% year-over-year, from 10M to 10M.
What is the long-term trend for Arcutis Biotherapeutics, Inc.'s convertible preferred stock authorized shares?
Over 4 years (2020 to 2024), Arcutis Biotherapeutics, Inc.'s convertible preferred stock authorized shares has grown at a 0.0% compound annual growth rate (CAGR), from 10M to 10M.
What does convertible preferred stock authorized shares mean?
Maximum number of convertible preferred shares the company is authorized to issue under its corporate charter.